Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands

NCT01215526 is registered in ClinicalTrials.gov with Ferring Pharmaceuticals as lead sponsor.

NCT NCT01215526
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01215526 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effectiveness and Safety of Firmagon® in Androgen Ablative Therapy of Advanced Hormone-dependent Prostate Carcinoma in the Netherlands
Lead sponsor
Ferring Pharmaceuticals
Phase
Observational
Overall status
Completed
Start date
October 31, 2010
Completion date
July 31, 2015
Enrollment
274 (actual)
Sites
47

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer